Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbetocin vs Misoprostol for PPH Prevention in High-Risk Vaginal Deliveries
NCT07353281Not yet recruiting
- Sponsor
- Galilee Medical Center
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Peptides
01
Overview
Randomised trial of carbetocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Galilee Medical Center. Primary endpoints: Postpartum hemorrhage at 24 hours and Need for additional uterotonic treatment or surgical intervention at 24 hours. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
carbetocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on NCT07353281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353281.